HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- ((2- piperidin- 1- ylethyl)thio)quinazolin- 4(3H)- one

structure in first source

Also Known As:

L 2286; L-2286; L2286 compound

Networked: 8 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - 2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one: 8
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - 2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one: 8

Experts

1.	Halmosi, Robert: 5 articles (01/2017 - 07/2006)
2.	Sumegi, Balazs: 5 articles (01/2017 - 07/2006)
3.	Toth, Kalman: 5 articles (01/2017 - 07/2006)
4.	Gallyas, Ferenc: 4 articles (01/2017 - 07/2006)
5.	Deres, Laszlo: 3 articles (01/2017 - 01/2014)
6.	Eros, Krisztian: 3 articles (01/2017 - 01/2014)
7.	Kalai, Tamas: 3 articles (01/2017 - 07/2006)
8.	Hideg, Kalman: 3 articles (07/2014 - 07/2006)
9.	Bartha, Eva: 3 articles (01/2014 - 10/2005)
10.	Magyar, Klara: 2 articles (01/2017 - 07/2014)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2017 - "In this study, we used Spontaneously Hypertensive Rats and normotensive Wistar-Kyoto rats with or without pharmacological inhibition of poly(ADP-ribose)polymerase-1 by an experimental compound L-2286, to evaluate carotid artery remodeling and consequent damage of neuronal tissue during hypertension. " 07/01/2014 - "L-2286 treatment decreased also the hypertension-activated mitochondrial cell death pathway, characterized by the nuclear translocation of AIF. "
2.	Craniocerebral Trauma (Head Injury) 03/26/2010 - "A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: an immunohistochemical and behavioral study."
3.	Myocardial Infarction 09/01/2008 - "Both L-2286 and enalapril were tested in a rat model of chronic heart failure after isoproterenol-induced myocardial infarction. " 10/01/2005 - "A novel PARP inhibitor, L-2286 [2-[(2-piperidin-1-yletil)thio]quinazolin-4(3H)-one] was administered during ischemia-reperfusion in Langendorff perfused rat hearts and in isoproterenol-induced myocardial infarction. "
4.	Hypertrophy 01/01/2014 - "L-2286 treatment decreased the marked left ventricular (LV) hypertrophy which was developed in SHRs. " 07/01/2006 - "More importantly, L-2286 repressed the hypertrophy-associated increased phosphorylation of panPKC, PKC alpha/betaII, PKC delta and PKC epsilon, which could be responsible for the activation of the antihypertrophic GSK-3beta. "
5.	Heart Failure 09/01/2008 - "In conclusion, we demonstrated in an experimental heart failure model that L-2286 decreased the postinfarction myocardial remodeling more effectively than enalapril treatment." 03/01/2021 - "L-2286, a quinazoline-derivative PARP inhibitor, protects against cardiovascular remodeling and heart failure by favorable modulation of signaling routes. " 09/01/2008 - "Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure." 09/01/2008 - "Both L-2286 and enalapril were tested in a rat model of chronic heart failure after isoproterenol-induced myocardial infarction. "

Related Drugs and Biologics

1.	Poly(ADP-ribose) Polymerase Inhibitors
2.	Isoproterenol (Isoprenaline)
3.	Protein Kinase C-epsilon
4.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
5.	Quinazolines
6.	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
7.	Enalapril
8.	Glycogen Synthase Kinase 3 beta